Lista de obras -

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

artículo científico publicado en 2019

A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade

artículo científico publicado en 2017

Alkylphenolic compounds and risk of breast and prostate cancer in the MCC-Spain study

scientific article published on 13 December 2018

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

artículo científico publicado en 2018

Changes in dietary intake, plasma carotenoids and erythrocyte membrane fatty acids in breast cancer survivors after a lifestyle intervention: results from a single-arm trial

artículo científico publicado en 2019

Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer

artículo científico publicado en 2018

Development and validation of a sexual relations satisfaction scale in patients with breast cancer - "SEXSAT-Q"

scientific article published on 17 August 2019

HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis

artículo científico publicado en 2020

Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.

artículo científico publicado en 2017

Multiparametric MR imaging to assess response following neoadjuvant systemic treatment in various breast cancer subtypes: Comparison between different definitions of pathologic complete response

artículo científico publicado en 2019

Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study

article

Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study

scientific article published on 31 May 2019

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

scientific article published on 20 January 2020

Quantified 99mTc-MIBI scintigraphy for predicting chemotherapy response in breast cancer patients: factors that influence the level of 99mTc-MIBI uptake ⬇️

artículo científico publicado el 1 de enero de 2002

Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of General Medicine (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), Span

artículo científico publicado en 2017

Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

scientific article published on 11 December 2019

SEOM clinical guidelines for the treatment of early breast cancer ⬇️

artículo científico publicado el 1 de noviembre de 2010

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

artículo científico publicado en 2019

Spanish Mediterranean diet and other dietary patterns and breast cancer risk: case-control EpiGEICAM study

artículo científico publicado en 2014

Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis

artículo científico publicado en 2015

p21WAF1/Cip1 is associated with cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma ⬇️

artículo científico publicado el 1 de marzo de 1998

Lista de obras de

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade

Alkylphenolic compounds and risk of breast and prostate cancer in the MCC-Spain study

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

Changes in dietary intake, plasma carotenoids and erythrocyte membrane fatty acids in breast cancer survivors after a lifestyle intervention: results from a single-arm trial

Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer

Development and validation of a sexual relations satisfaction scale in patients with breast cancer - "SEXSAT-Q"

HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis

Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.

Multiparametric MR imaging to assess response following neoadjuvant systemic treatment in various breast cancer subtypes: Comparison between different definitions of pathologic complete response

Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study

Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

Quantified 99mTc-MIBI scintigraphy for predicting chemotherapy response in breast cancer patients: factors that influence the level of 99mTc-MIBI uptake ⬇️

Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of General Medicine (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), Span

Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

SEOM clinical guidelines for the treatment of early breast cancer ⬇️

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

Spanish Mediterranean diet and other dietary patterns and breast cancer risk: case-control EpiGEICAM study

Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis

p21WAF1/Cip1 is associated with cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma ⬇️